Full Name | Vowst™ (fecal microbiota spores live-brpk) |
Drug | Vowst |
Manufacturer | Aimmune Therapeutics |
Route of Administration | Oral |
Site of Care | Home |
Approved Indication | Prevent the recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI) |
Disease | Recurrent C. difficile Infection (rCDI) |
Therapeutic Area | Infectious Disease; Gastroenterology |
Enrollment Form Link | Enrollment Form |
Phone Number | 800-485-4885 |
Fax Number | 877-640-5179 |
Product Website | vowsthcp.com |
About Recurrent C. difficile Infection (rCDI)
Recurrent C. difficile infection is a gastrointestinal condition caused by the bacteria Clostridium difficile. It stems from an imbalance, known as dysbiosis, in the gastrointestinal microbiome. Associated with heightened morbidity and mortality, rCDI has been classified as an Urgent Health Threat by the Centers for Disease Control and Prevention (CDC).